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1. Introduction. Primary headaches and migraine 
Headache is one of the mostly investigated complaints, whereby doctors meet. 
Headache could be a symptom of severe, life threatening disease, however in most of the 
cases it is only a benign tension type headache or migraine. The headaches are divided into 
four major categories by the classification of International Headache Society (IHS 2004). 
Primary headaches belong to the first group, as the migraine, tension type headache, 
trigeminal autonomic cephalalgias and other primary, infrequent headaches. Primary 
headache is estimated to the main group of cephalalgias, because 87% of the headaches are 
non organic. The group of secondary cephalalgias subsume headache attributed to head and 
neck trauma, cervical or vascular disorder, non vascular intracranial disorder, substance or its 
withdrawal, infection, disorder of homeostasis, disorder of cranium, neck, eyes, ears, nose, 
psychiatric disorder, these entities add up the 10% of all headaches. In the third group 
comprise the rarer concurrent headaches as cranial neuralgias and central or primary facial 
pains. According to former studies 47% of the population suffer from recurrent headaches, 
within this group 10% of the patients have migraine, 38% have tension type headache and 3% 
of the patients have chronic headaches. We are disposed to believe that headaches are simply, 
not too severe diseases, nevertheless this does not mean, that headaches are not represent 
remarkable burden for economy. Under international data (USA, UK) the prevalence of 
migraine is 12% and 70% of migraine patients need cure during the headache. This doesn’t 
mean generally an outpatient or bed-case management, because the major part of patients can 
cure the headache self with certain medicaments. However through this time most of the 
patients are unable to work or learn. When international data are projected to Hungary, 
migraine results 1.4 million drop-out workdays and 2.8 million workdays with decreased 
efficacy per a year. According to European Union data, migraine is the most expensive 
disease from neurological disorders amounts 27 billion Euro per a year, the major part derives 
from indirect cost means drop-out workdays and workdays with decreased efficacy.  
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2. Aims of the investigations 
In the thesis three different questions were investigated in the theme of primary 
headaches. 
First, we investigated in our own migraine patients, with and without white matter 
hyperintensities (WMH), migraine history and risk factors were analyzed, which can lead to 
the development of migraine related white matter hyperintensities. 
In the second part the hypothetical association was analyzed between the migraine and 
magnesium deficiency. Further investigations referred that Mg deficiency plays etiological 
role in the pathogenesis of migraine. Whereas Mg is mainly intracellular cation, thereby a 
simple serum Mg measurement not gives us true information about the whole body Mg 
content. Therefore the total body Mg content was investigated with a per oral Mg load test in 
the comparison between the group of patients with migraine and healthy volunteers. 
In the third part a trigeminal autonomic headache, SUNCT (Short Lasting Unilateral 
Headache with Nasal Conjunction and Tearing) syndrome was studied. We investigated the 
periods of our three patients, and we found a new, effective short-term prevention therapy, 
which can be offered for the treatment of SUNCT.  
 
3. Risk factors of migraine-related white matter hyperintensities 
3.1. Migraine and white matter hyperintensities: introduction 
Migraine is not as benign a disease as it was thought before the imaging era since 
migraine is an independent risk factor for deep white matter lesions, silent posterior 
circulation territory infarcts, and infratentorial hyperintense lesions. Migraine patients have an 
almost fourfold greater risk to develop white matter lesions than non-migraine controls, and 
the prevalence of these lesions is higher in migraine with aura than in migraine without aura. 
The risk of developing white matter lesions is higher in female migraineurs and in patients 
with higher attack frequency and longer disease duration. Furthermore, it seems that brain 
white matter lesions do not correlate with age. Brain white matter hyperintensities are 
frequent, but not specific alterations in the MRI, under its definition small, punctual (3-7 mm) 
lesions in the perinventricular or in the deep white matter, appear in the T2 and FLAIR 
sequences of the MRI, but not can be seen in the T1 sequence.  
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 The clinical significance of white matter hyperintensities (WMH) is uncertain and the 
pathogenesis of these lesions is likely multifactorial. A number of pathophysiological 
mechanisms have been proposed including attack-related oligemia and focal hypoperfusion, 
glutamatergic excitotoxicity, immune-based white matter demyelination, and mitochondrial 
dysfunction. Several studies considered the role of inflammation as a vascular risk for brain 
white matter lesions in migraine. Elevated C-reactive protein found in migraine patients is a 
sensitive indicator of active systemic inflammation and a marker of oxidative stress. Increased 
proinflammatory cytokines (IL-1, IL-6, TNF-a) have been reported during acute migraine 
attacks, as well as in the interictal periods. Repeated sterile vascular inflammation results in 
endothelial injury of the cranial blood vessels, cranial arteriopathy, and consequent 
thrombosis. It has been suggested that cortical spreading depression causes disruption of the 
blood brain barrier through a matrix metalloproteinase-9-dependent cascade mechanism 
which may result in local tissue damage. It is also known that endothelial dysfunction 
associates with an increased rate of cerebrovascular ischemic events, and genetic factors (such 
as angiotensin converting enzyme insertion/deletion, methylenetetrahydrofolate reductase 
C677T polymorphisms, and von Willebrand factor activity) which increase the susceptibility 
of endothelial dysfunction have been linked to migraine. 
Although migraineurs, particularly with aura, have a higher cardiovascular risk profile 
than individuals without migraine, the presence of white matter lesions proved to be 
independent of a history of hypertension, diabetes, smoking, hypercholesterolemia, 
hyperhomocysteinemia, patent foramen ovale with right-to-left shunt, and oral contraceptive 
use. Associations with antiphospholipid antibodies (anticardiolipin antibodies, lupus 
anticoagulans) and abnormal coagulation parameters (antithrombin-III, protein S, protein C) 
were also not found. Because of the high prevalence of white matter hyperintensities, and the 
partly contradictory and uncertain etiological data, we have investigated the possible risk 
factors for subclinical brain white matter hyperintensities in our own migraine patients by 
analyzing their routine clinical data. 
 
3.2. Patients and methods 
3.2.1. Subjects and studies 
Subjects included in this study were referred to the Outpatient Headache Department 
of the Department of Neurology, Medical School, University of Pécs, Hungary between 2007 
and 2009. All the patients who were chosen for the study met the criteria of migraine patients 
as defined by the International Headache Society. Further, patients were also selected based 
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on the lack of major comorbidities, such as hypertension, cardiac disease, diabetes, thyroid 
gland dysfunction, oncological and haematological diseases, infectious diseases (e.g. HIV, 
hepatitis), central nervous system demyelination (e.g. multiple sclerosis), and genetically 
inherited disorders (e.g. CADASIL). Altogether 186 migraine patients were investigated in 
the study (141 patients without aura, 45 patients with aura, age range 18–58 years, mean age 
36.4 years, SD: 8.9; 156 females and 30 males). Based on the findings of brain magnetic 
resonance imaging (MRI) studies, patients were divided into two groups: patients with WMH 
(WMH group, n = 58, mean age 40.2 year, 54 patients had supratentorial hyperintensities, 4 
patients had cerebellar hyperintensities) and patients without WMH (WMH group, n = 128, 
mean age 34.9 year). 
All participants underwent a structured clinical examination (history taking, physical 
examination, blood pressure measurement, serum and urine tests, brain MRI study) to identify 
comorbid medical disorders. Gender, migraine type, disease duration, attack frequency, 
history of smoking and taking oral contraceptives, serum cholesterol LDL, uric acid, 
homocysteine levels, and thyroid-stimulating hormone levels with thyroxine and 
triiodothyronine when necessary were routinely examined. In all cases when aura symptoms 
and/or WMH were present, patients were tested for vasculitis (antinuclear antibody, 
antineutrophil cytoplasmic autoantibody, antiphospholipid antibody, lupus anticoagulant), for 
Lyme disease (serum ELISA screening with Western blot testing), and for patent foramen 
ovale (transthoracic and transesophageal echocardiography). 
3.2.2. MRI protocol 
The brain MRI examinations were carried out with an MR scanner operating at 3 T 
(Siemens Trio Tim, 12 channel head coil). A qualified neuroradiologist who was blinded to 
migraine diagnosis and clinical data rated the WMH. WMH were considered if visible as 
hyperintense on T2- weighted and FLAIR images, without hypointensity on T1- weighted 
scans, and were larger than 3 mm. 
3.2.3. Statistical analysis  
Statistical analysis was performed using the SPSS 15.0 statistical package (SPSS Inc., 
Chicago, IL, USA). Chi-square, Fisher’s exact test, non-parametric Mann–Whitney and 
finally a binary logistic regression was performed to predict the presence of WMH from a set 
of independent variables.  
3.3. Results 
1. There was no statistical difference between females (n=48 out of 156, 30.7%) and males 
(n=10 out of 30, 33.3%), as well as between migraine patients without aura (n=42 out of 141, 
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30.5%) and patients with aura (n=16 out of 45, 35.6%) in relation to the presence of WMH 
(Table 1). 
Table 1. Patients 
WMH+patients n percentege of patients 
women 48/156 30.7% 
men 10/30 30.33% 
migraine without aura  42/141 30.5% 
migraine with aura 16/45 35.6% 
 
2. The number of patients with WMH increased with the increase of disease duration, in 
patients with above 20 migraine years hyperintensities were significantly more frequent than 
in those with less than 20 years of duration (under 20 years n=28/120, 23.3%, above 20 years 
in n=30/66, 45.6%, p=0.007). When examining the association between the disease duration 
and the presence of WMH according to migraine type, it was found that both migraine 
patients without and with aura have a longer disease duration with WMH, than patients 
without WMH (Table 2). 
Table 2. Differences between the WMH- and WMH+ groups in relation to disease duration and attack frequency 
in migraine patients without and with aura 
   Patient 
number 
 
Disease 
duration 
 
p-value Attack 
frequency 
p-value 
  [years]   [attack/month]   
All patients WMH- 128 14.3±8.5 0.004 4.1±3.0 0.017 
WMH+ 58 19.9±11.6 5.5±3.6 
Patients without aura WMH- 99 14.7±8.7 0.3 4.6±3.1 0.017 
WMH+ 42 19.7±11.7 6.2±3.6 
Patients with aura WMH- 29 13.1±7.9 0.047 2.4±2.4 0.067  
WMH+ 16 20.3±11.8 3.5±3.0 
WMH- patients without white matter hyperintensities, WMH+ patients with white matter hyperintensities. The 
diseases duration and attack frequency values are presented in mean ± 1 SD. 
p values are based on Mann–Whitney statistical analysis 
 
3. Although the proportion of migraine patients with WMH increased with the monthly 
migraine attack frequency (0–1 attack/month: n=7/37, 18.9%, 2–7 attacks/month: n=36/114, 
31.5%, C8 attacks/month: n=15/35, 42.9%), there was only a trend towards statistical 
significance (p=0.08) when the patients were examined in three groups according to their 
attack frequency. Conversely, when the attack frequency of the WMH+ group was compared 
to the attack frequency of the WMH- group, a significantly higher attack number was found in 
the WMH+ group (Table 2). When examining the effect of attack frequency on the presence 
of brain WMH in migraine subgroups, it was found that migraine patients without aura and 
with WMH have a higher attack frequency than patients without aura and without WMH 
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(Table 1). In patients with aura the same tendency was seen, but the difference was not 
statistically significant (Table 2). 
4. WMH did not occur more frequently in smokers (n=18/52, 34.6%) than in non-smokers 
(n=40/134, 29.8%), but smoking was significantly associated (p=0.001) with increased 
monthly attack frequency (\5 attacks/month: n=87/134, 64.9% in non-smokers, n=47/134, 
35.0% in smokers, C5 attacks/month: n=20/52, 38.4% in non-smokers, n=32/52, 61.5% in 
smokers). 
5. There was a significant relation between abnormally high serum homocysteine levels and 
the incidence of brain WMH; out of 60 patients tested for serum homocysteine 9 had WMH 
and homocysteine levels were elevated in all 9 patients (p=0.009). 
6. Subclinical hypo- (n=8) and hyperthyroidism (n=6) was detected in 14 patients (14/186= 
7.5%). Out of these patients, eight had WMH (4 patients in both groups, 8/14=57.1%). 
Statistical analysis showed the subclinical thyroid dysfunction occurred significantly more 
frequently in the WMH+ group than in the WMH- group (p=0.038). 
7. Although the statistical analysis did not show an increased risk of WMH in migraineurs 
with high cholesterol, LDL cholesterol (p=0.06) and high uric acid levels (p=0.07), the 
cholesterol, LDL cholesterol and uric acid values were found more frequently in the elevated 
range in the WMH+ group (n=18/41, 43.9% for cholesterol, LDL cholesterol, n=7/15, 46.6% 
for uric acid) than in the WMH- group (n=40/145, 27.5% for cholesterol, LDL cholesterol, 
n=51/171, 29.8% for uric acid). 
8. When the effects of all the predictor variables were examined, only two good predictor 
variables were found: the disease duration (p<0.01) and the attack frequency (p<0.05) (Table 
3). There was no significant effect with all the other variables (p>0.1) (Table 3) 
Table 3. Results of binary logistic regression for white matter hyperintensities 
 Examined variables p-value OR 95% CI or OR 
lower                     upper 
Step 1  Disease duration 0.090 1.046 0.993 1.103 
Attack frequency 0.018 1.164 1.026 1.321 
Age 0.913 0.997 0.947 1.049 
Gender 0.865 1.087 0.414 2.855 
Smoking 0.249 0.584 0.234 1.457 
Thyroid function 0.289 0.637 0.277 1.465 
Cholesterol 0.135 0.498 0.200 1.242 
Uric acid 0.447 0.515 0.093 2.849 
Step 7 Disease duration 0.005 1.051 1.015 1.089 
Attack frequency 0.017 1.153 1.026 1.295 
The table presents the p value, the odds ratio (OR) and the 95% confidence interval (CI) for the OR for all of the 
variables at Step 1 and for the variables that were significant at Step 7 of the backward stepwise elimination 
procedure  
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9. An elevated antiphospholipid antibody titer was only found in one patient. 
Echocardiography showed a tiny patent foramen ovale with right to left shunt in two migraine 
patients with aura and with brain WMH. There was no patient with pathologic Lyme 
serology. 
 
3.4. Discussion 
In this study, we have investigated possible risk factors for brain WMH based in 
migraine history and blood tests. To get more accurate data on those factors which may 
influence the formation of WMH, diseases which can associate with the presence of brain 
WMH without migraine, including hypertension, were excluded from our study. We found 
significantly higher hyperintensity incidence in patients with longer migraine duration, higher 
headache frequency, subclinical hyper- and hypothyroidism, and elevated plasma 
concentrations of homocysteine, while in the cases of cholesterol and uric acid, there was a 
trend towards statistical significance. Statistical difference was not found between migraine 
patients without and with aura in relation to the presence of WMH, but most of the patients in 
the WMH+ group had only supratentorial signal abnormalities. There are differences between 
our results and the previously documented ones, and we suppose that these are based on the 
limitations of the performed studies due to differences in patient selection and sample size. 
The relation between disease duration and attack frequency to the WMH is not surprising if 
we take into account the pathophysiology of migraine. During the attack several intracranial 
pathologic processes are detectable, including intracerebral haemodynamic changes, local 
inflammatory responses, excessive neuronal activation and excitotoxicity, which may all lead 
to tissue damage. Although there are regional differences and predilection sites for tissue 
damage, basically, the migraine attack affects the whole brain. It is known that there are 
differences among migraine patients in relation to the risk of the WMH. The risk depends not 
only on the disease duration and frequency, but the migraine type, attack duration, and 
comorbid conditions can also influence it. The comorbid conditions are mainly routine stroke 
risk factors and these may lead to tissue damage by direct (e.g. blood vessel endothelium 
dysfunction, hypercoagulation, embolization) or indirect (e.g. smoking) effects. In our study, 
the occurrence of WMH was not higher in smokers than in non-smokers, but smoking 
increased the headache frequency, therefore smoking may indirectly cause white matter 
hyperintensities. These data are consistent with the previously reported ones showing higher 
prevalence rates for headache amongst smokers compared to non-smokers. 
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Plasma homocysteine concentration is controlled by genetic (MTHFR C677T 
mutation), nutritional(vitamins, folate, B6, B12) and acquired (smoking, alcohol consumption, 
renal diseases, malignancies, inflammation, daily physical activity) factors. It has been found 
that migraine patients with aura who are homozygotes for methylene-tetrahydrofolate 
reductase (MTHFR) C677T variant, are at risk for elevated levels of homocysteine, and 
homocysteine-related endothelial dysfunction may be involved in the initiation and 
maintenance of migraine. 
Although subclinical thyroid gland dysfunction was found in few patients in our study, 
more than half of these patients had brain WMH. Subclinical thyroid gland dysfunction can be 
a risk factor for WMH in migraine, but currently there is no definite evidence to confirm this. 
Hyperthyroidism can associate with atrial fibrillation and cardioembolic stroke and may lead 
to a hypercoagulability state. Hypothyroidism is associated with a worse cardiovascular risk 
factor profile including elevated cholesterol and lowdensity lipoprotein levels, diastolic 
hypertension, increased homocysteine and C-reactive protein concentrations, impaired thyroid 
hormone action on target tissue by smoking, tendency toward decreased fibrinolytic activity 
in mild and moderate hypothyroidism, and endothelial dysfunction with progression to 
atherosclerosis. 
We found WMH more frequently in our migraine patients with elevated serum 
cholesterol and uric acid levels, and we speculate that if there is a relation between migraine 
and cholesterol and uric acids levels, this can be based on altered endothelial dysfunction and 
migraine attack frequency. The presence of hypercholesterolemia and dyslipidemia in patients 
with migraine may increase the risk of vascular wall injury. Hypercholesterolemia is 
associated with an increase in endothelial permeability, the retention of lipoproteins within the 
intima of blood vessels, inflammatory cell recruitment and foam cell formation filled with 
oxidative-LDLs, and finally these processes progress to atherosclerotic plaque maturation. 
Cholesterol crystals, a component of human atherosclerotic plaques, could also cause an 
inflammatory response and neuronal injury in the brain with persistent activation of microglia 
and astrocytes via microembolization. Furthermore, a number of epidemiologic data show that 
an elevated serum uric acid level is a powerful predictor of an increased risk of a 
cardiovascular event including stroke and silent brain infarcts, however, the available data are 
contradictory. It is entirely plausible that chronic elevations in serum uric acid levels have 
harmful effects on platelet, smooth muscle, and endothelial function, but the neuroprotective, 
antioxidant effect of high uric acid levels may associate with improved outcome in the peri-
ictal period. In conclusion, this study provides additional data on the etiology of migraine-
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related WMH supporting the former assumptions that a wide range of factors contribute to 
lesion formation. These include attack-related intracerebral changes and direct or indirect 
effects of comorbid diseases. 
Development in understanding the pathophysiology of migraine and the pathology of 
WMH, the use of effective therapy for migraine attack and prophylaxis, detection and 
treatment of vascular risk factors, and avoiding smoking may help to prevent the development 
of the hyperintensities. 
 
4. Oral Magnesium load test in patients with migraine 
4.1. Introduction 
 Magnesium is an essential intracellular cation in the body, the fourth mostly occurring 
mineral agent, and it is involved in numerous physiological processes. Magnesium is a 
cofactor of more than 300 physiological processes, it plays a role in the synthesis of DNA, 
RNA, protein, in the production of energy (ATP-Mg complex), and stabilize the membrane of 
the mitochondria. Magnesium has in important function in the metabolism of bones. Mg 
counts as a natural Ca antagonist, because it is able to activate the Na-K-ATP-ase, able to 
inhibit the influx of Ca into the cell. Mg participates in action of neuromuscular junction 
(inhibit the excretion of Ach in the nerve terminal, stabilize the sarcolemma), in muscle and 
cardiac cell contraction, in balancing of blood pressure, in the metabolism of glucose and 
insulin. 
 The Mg content of the adult human is approximately 25 g, 60% of the total amount is 
in the bones, 40% is in the muscle cells or other soft tissues, and less than 1% of the total 
body Mg is present in the blood. Mg mainly an intracellular cation, the main store is the bone, 
in case of Mg deficiency it could be evolved from the bones, but it is a time-consuming 
procedure, it takes a few weeks. Therefore the Mg deficiency cannot be equalized fast, 
accordingly the serum Mg level cannot reflect the correct Mg content of the body. The shift 
between the intra- and extracellular part is a slow process; it is controlled by the 
electrochemical gradient, but there is also known an ATP dependent Na-Mg changer ion 
pump. Therefore Mg loss from the serum results continent Mg deficiency and in the other 
hand along normal serum Mg level, intracellular Mg deficiency can be existed. The serum Mg 
level is controlled by the kidney, to reach the normal level women need 300 mg, men need 
380 mg Mg intake per a day. 
 The development of Mg deficiency is usually due to dietary alterations. Under certain 
studies 75% of the population in USA cannot obtain to the advisable Mg intake. The 
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inadequate alimentation, the low Mg content in fruits and vegetable, the alcohol consumption, 
and certain drugs (diuretics) usage leads to the development of Mg deficiency. In Hungary we 
also had a study, which investigated the Mg intake of the population, the average intake in 
women was 372 mg, in men 441 mg, this is corresponds to the normal amount, but individual 
alterations cannot be expelled. Significant Mg deficiency can be developed in case of 
vomiting, diarrhea, hypercalciuria, glucosuria, usage of diuretics, regularly alcohol 
consumption. Hungry bone syndrome can develop after the operation of hyperparathyreosis. 
The most symptoms of Mg deficiency are not specific. In the cerebral form the main 
symptoms are headache, migraine, vertigo, nystagmus, loss of concentration. 
 Based on a previous studies showing evidence of Mg reduction in patients with 
migraine, Mg deficiency may play an important role in migraine pathogenesis. Low levels of 
Mg increase the aggregation of the platelets, therefore serotonin is able to evolve leading to 
intracerebral arterial vasoconstriction. The increased level of serotonin is responsible the 
excretion of substance P, which plays a part of the evolution of pain. Besides Mg has a Ca-
channel blocking effect, Mg is able to control the influx of Ca into the endothelial and muscle 
cells, therefore in case of Mg deficiency Ca channels act more active, vasoconstriction 
develops more easily. Reduced Mg level enhance the sensitivity of the NMDA receptors to 
glutamate, facilitating the development of cortical spreading depression. The evidence that 
Mg plays a part in the initiation of primary headache is the observation that in case of 
migraine or cluster headache administration of 1 g MgSO4 can terminate the symptoms.  
The measurement of serum magnesium is widely used to assess total body Mg status, 
but normal serum Mg concentration also can occur in the presence of tissue Mg depletion 
with the compensation of by the bone Mg pool. Intracellular Mg content (from leucocytes, 
lymphocytes, red blood cell, platelets) has been investigated in the hope that it would be a 
better indicator of Mg status than the serum Mg concentration, but intracellular Mg 
concentration pools do not seem to correlate with other tissue pools. The most accurate 
methods to asses Mg status are the Mg load test and muscle or bone biopsies. Mg load test 
was use in earlier to investigate the Mg deficiency in case of fatty acid malabsorption and 
protein-calorie malnutrition in elderly. Normally 80 % of the Mg intake can excrete by the 
kidneys under 48 hours. 
In the study reported here, we sought to determine the total body Mg status of patients 
with migraine by administering an oral Mg load test and comparing the migraineur’s serum 
and urinary Mg concentrations with those obtained from healthy subjects. 
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4.2. Patients and methods 
4.2.1. Subjects 
We evaluated 20 patients with migraine (15 women and 5 men; mean age, 37.9 years; 
age range, 16 to 52 years) and 20 healthy age-matched volunteers (16 women and 4 men; 
mean age, 39.6 years; age range, 21 to 54 years). The clinical diagnoses of the patients with 
migraine were based on the headache classification system of the International Headache 
Society (HIS 1988). Sixteen patients having migraine without aura (IHS 1.1), and 4 patients 
experiencing migraine with aura (IHS 1.2) were treated. The Mg load test was performed 
during an attack free period in all patients. Patients and subjects with a history of Mg 
supplementation within the year prior to the load test or those with special dietary habits were 
excluded from the study. To reduce the methodological limitations resulting from differences 
in body weight, we selected subjects who had a normal body mass index and less than 10% 
variation in body weight from fellow subjects. Neither the controls nor the patients were 
taking any medication known to interfere with Mg status, none of them have chronic disorder 
bordering internal medicine. Alcohol intake and heavy physical activity were not allowed 
during the collection periods. 
 
4.2.2. Magnesium loading and sample collection 
The Mg load test was performed on 2 consecutive days. In order to determine the 
baseline serum Mg levels and the baseline urinary Mg excretions, blood was obtained, in the 
morning of the first day, followed by a 24-hour urine collection. On the second day, three 
divided 1000-mg doses of Mg lactate were administered orally to each subject, and a 24-hour 
urine specimen was collected. To determine the post load serum Mg levels, venous blood was 
drawn at the end of the second day. 
 
4.2.3. Sample preparation and measurement 
The concentration of Mg in serum and urine was measured by a Varian spectrAA-20 
atomic absorption spectrophotometer. In our laboratory, the reference ranges for Mg 
concentration are 0.70 to 1.00 mmol/L for serum, and 2.2 to 5.6 mmol/24 hours for urine. 
 
4.2.4. Statistical analysis 
Statistical analysis was performed using Statistica for Windows version 5.1 statistical 
package (StatSoft, Inc, Tulsa, Okla). Paired t test, Pearson correlation, F-test was used. 
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4.3. Results  
1. The mean serum and 24-hour urine Mg concentrations obtained before and after Mg 
loading are listed in the Table 1.  
Table 1. Serum and urine Mg concentrations 
 serum Mg concentration mmol/l urine Mg excretion mmol/24 hour 
control (n=20) migraine (n=20) control (n=20) migraine (n=20) 
Before Mg load 0.81±0.08 0.80±0.04 3.99±1.51 3.18±1.18 
After Mg load 0.89±0.11 0.86±0.07 5.9±1.63 4.16±1.33 
±Values are means SD. 
 
The baseline serum Mg values were within the reference range in both groups, while the 
baseline Mg values from the 24-hour urine collection were below normal in four migraineurs 
and in one control subject. 
2. The baseline serum Mg concentrations and urinary excretions increased in all subjects after 
Mg loading. Although the serum Mg levels were somewhat lower in the patients with 
migraine than in the controls before and after Mg administration, this difference was not 
significant. Preload urinary Mg excretion was lower in the patients with migraine than in the 
normal subjects, but the difference, too, was not significant (p=0.064). After loading, 
however, the Mg excretion of the patients with migraine was significantly lower than that of 
the controls (p=0.0007). Within the groups, significant correlations were not found in the 
comparison of serum Mg concentrations in the 24-hour urine excretion values in either the 
preload or the postload periods. 
 
4.4. Discussion 
 It is thought there is possible relationship between Mg deficiency and the development 
of migraine. In case of Mg deficiency platelet aggregation and therefore the consecutive 
release of serotonin from platelets may increase, this can provoke arterial vasoconstriction. In 
the other hand it can enhance the sensitivity of NMDA receptors enlarging the risk of 
development of CSD.  
Previous ictal and interictal studies of patients with migraine have revealed reduced 
levels of Mg concentrations in serum, saliva, red blood cells, mononuclear cells, lymphocytes, 
cerebrospinal fluid, and brain. In other investigations, a deficiency of Mg has been less 
evident or altogether lacking. Measurements of intracellular and ionized Mg concentrations 
are sensitive methods for demonstrating Mg deficiency, but because there is little evidence for 
dynamic equilibrium among body tissues, these methods give only limited information about 
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total body Mg status.. For this reason, we chose the widely accepted Mg load test in our effort 
to determine whether systemic Mg deficiency exists in patients with migraine.  
The baseline serum and urine Mg concentrations recorded in our migraine and control 
groups did not differ significantly. These results are consistent with previous reports showing 
normal total serum Mg levels in patients with migraine in both the ictal and interictal states. 
The 24-hour urine excretion of Mg may be a better indicator of tissue status than the serum 
Mg concentration, but urinary Mg excretion is highly variable and so cannot be used reliably 
to assay a given individual’s Mg status. After loading, Mg levels in serum and in excreted 
urine increased significantly in both of our subject groups, simply demonstrating the 
absorption and bioavailability of orally administered Mg. Urinary Mg excretion did not 
correlate with serum Mg concentration indicating that renal excretion values reflect the 
complex interrelations of the different Mg pools. The post load serum Mg concentrations did 
not differ between our two groups, but the Mg content in the excreted 24-hour urine was 
significantly lower in the migraine group than in the control group. In short, our patients with 
migraine retained more Mg than our control subjects, and such retention is considered to 
reflect systemic Mg deficiency.  
There are numerous etiologies for primary and secondary Mg deficiency. Deficiency 
may be due to reduced dietary intake, smoking, consumption of alcohol, intestinal 
malabsorption and defective membrane transport, stress, or genetically impaired intracellular 
regulations. Females have a greater tendency for Mg deficiency than males, presumably 
nonresponders exhibited significantly higher baseline total Mg levels than responders. In two 
double-blind, placebo- controlled studies evaluating oral supplementation for migraine 
prophylaxis, patients receiving Mg experienced reductions in attack frequency and number of 
days with headache. In the third trial of Mg prophylaxis, no difference in efficacy was 
observed between the migraine and placebo groups; poor absorption of the Mg salt selected 
was blamed for the negative result. In conclusion, the oral Mg load test may represent an 
effective, noninvasive means for detecting systemic Mg deficiency in patients with migraine. 
It should be noted that this test requires strict subject cooperation and has not been 
standardized for routine clinical use. Even so, our data add to the growing amount of literature 
supporting the role of Mg deficiency in the pathogenesis of migraine. 
 
 
 
16 
5. Methylprednisolone therapy for short-term prevention of SUNCT syndrome 
5.1. Introduction 
Trigeminal autonomic cephalalgia (TAC) is a collective term that refers to a group of 
headaches characterized by episodic or chronic, short-lasting, unilateral head or face pain with 
accompanying autonomic features. TACs include cluster headache, paroxysmal hemicrania 
and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and 
tearing (SUNCT). The pathophysiology of TACs involves activation of trigeminovascular 
nociceptive pathways with cranial autonomic activation, which is due to central disinhibition 
of the trigeminal autonomic reflex by the hypothalamus. 
Despite the fact that TACs share common pathophysiological pathways, there are 
dissimilarities among the headache syndromes not only in the basic clinical features (e.g. in 
SUNCT the duration of pain and autonomic symptoms is the shortest, the incidence of daily 
attacks is the highest), but also in response to therapy. Most of the current treatment options 
for TACs are rather empirical than pathophysiology-based, and little is known concerning the 
mechanism of action of the pharmacological agents used as acute and prophylactic therapy. In 
cluster headache and in paroxysmal hemicrania there are some accomplished and well-
tolerated, therefore recommended, acute and preventive medications. However, in the rare 
SUNCT syndrome we have only case reports with frequently disappointing therapeutic 
effectiveness. Abortive therapy of SUNCT is meaningless because of its characteristic short 
and frequent pain attacks. Intravenous lidocaine has been suggested for short-term prevention, 
but this treatment requires hospitalization, and complete pain relief was only in a fraction of 
the treated patients reported. Among all medications attempted in SUNCT, lamotrigine was 
most effective for long-term prevention, but patients need to be particularly vigilant during 
the initiation of therapy because of possible skin reactions, which may even progress to 
Stevens–Johnson syndrome. The risk can be reduced by slow introduction and titration; 
however, during this period, which might last for a few weeks, the patient has no efficient 
symptom relief. In cluster headache corticosteroids are very effective in suppressing the 
headache period and are therefore recommended for short- term prevention. In SUNCT 
syndrome only a few corticosteroid-treated cases have been reported with partial 
effectiveness.  
During the past few years, only three patients with idiopathic, episodic SUNCT 
syndrome were referred to our Outpatient Headache Department. All patients had been 
unsuccessfully treated during their previous headache periods. Based on the success of cluster 
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headache corticosteroid treatment, we tried methylprednisolone therapy for short-term 
prevention in all three patients to minimize their disability during the headache period. 
 
5.2. Case histories 
5.2.1. Patient 1  
A 60-year-old man was examined for frequent headache paroxysms (15–40/day) lasting 30–
150 s with few minutes-long refractory periods between the attacks. Although most of his 
attacks were spontaneous, he could sometimes trigger the headaches with forced and repeated 
eye closure. The left-sided orbital/supraorbital pain [intensity 10/10 on the visual analogue 
scale (VAS)] was associated with ipsilateral cranial autonomic symptoms such as conjunctival 
injection, tearing, eyelid oedema, nasal congestion and rhinorrhoea. The headaches occurred 
in cluster periods, once or twice every year, lasting for 30–60 days for 13 years. There was no 
chronic disorder in his medical history and he was not on regular medication. He did not 
smoke and there was no history of other headaches. Neurological and ophthalmological 
examinations, routine blood tests and 3T brain magnetic resonance imaging (MRI) studies 
were normal. Previous treatments with non-steroid anti-inflammatory drugs (NSAIDs; 
diclofenac, ibuprofen, indomethacin, naproxen), carbamazepine, gabapentin and pregabalin 
had not proved effective. He took methylprednisolone in a daily dose of 1 mg/kg for 2 weeks, 
then in reduced dose (16 mg dose reduction/week) for 4 weeks. The therapy had been 
repeated four times during the last 3 years. The medication was started on the first day of the 
headache bout in each period, and the steroid therapy lasted for 4–6 weeks. To decrease the 
possible side-effects of corticosteroid treatment, the histamine H2 receptor antagonist 
famotidine in a daily dose of 80 mg and potassium chloride in a daily dose of 1000 mg were 
co-administered with the methylprednisolone therapy. His pain intensity and the number of 
daily headaches decreased dramatically within 48 h, and then he became attack-free in all 
treated periods. Treatment-related side-effects did not occur.  
 
5.2.2. Patient 2  
A 75-year-old non-smoker man had suffered from repeated headache periods for 11 years. 
The periods lasted for 20–40 days and had appeared not more than once per year during 
periods of weather transition in the spring or autumn. He complained of stabbing and burning 
pain in the left orbital, and periorbital regions along with tearing and conjunctival injection. 
The intensity of his headaches measured by VAS was 10/10. The duration of pain attacks was 
45–120 s and the headaches occurred 20–70 times every day without triggering refractory 
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periods between the attacks. There was no reported nausea or vomiting, and he could trigger 
the attacks with speaking, eating and face grimacing. The patient did not have any other type 
of headache. His medical history consisted of well controlled type II diabetes, hypertension 
and cardiac atrial fibrillation. Neurological, ophthalmological and otorhinolaryngological 
examinations were normal; a routine blood test showed only an increased International 
Normalized Ratio level, which was explained by chronic anticoagulant therapy. 3T brain MRI 
images demonstrated small signal abnormalities in the hemispheric white matter, but the 
brainstem was intact and there was no sign of trigeminal nerve vascular or nonvascular 
compression. Previous medications including NSAIDs (diclofenac, ibuprofen), clomipramine, 
carbamazepine, gabapentin and pregabalin did not alleviate the symptoms. He was treated 
with methylprednisolone (1 mg/kg every day) during his last two headache periods. The 
therapy started on the first day of the attacks in each period, and both the intensity and 
frequency of the attacks improved within 3 days and then he became pain-free. The 
corticosteroid treatment was tapered after 2 weeks by 4 mg every day and was finally 
discontinued within 3 weeks. The remission was maintained during the treatment period and 
the headaches did not relapse afterward. To decrease the possible side-effects of corticosteroid 
treatment, the histamineH2 receptor antagonist famotidine at a daily dose of 80 mg and 
potassium chloride at a daily dose of 1000 mg were co-administered with the 
methylprednisolone therapy. The dose of his regular oral antidiabetic drug was increased 
during the treatment period. The patient tolerated the treatments well during both period 
 
5.2.3. Patient 3 
A 27-year-old man had reported his first headache period 8 years before his neurological 
examination. The short-lasting (5–45 s), frequent (up to 100/day), severe (10/10 in intensity 
by VAS) and unilateral headaches developed in his right temple, eye and upper teeth. There 
was no refractory period between the attacks. The pain was sharp and stabbing. There was no 
nausea, light or noise sensitivity. The headaches were associated with ipsilateral conjunctival 
injection, tearing and nasal congestion. The pain could be triggered by touch of the forehead, 
temple and chin, as well as by chewing, drinking cold water and brushing of teeth. The 
headache period occurred twice per year (spring and autumn) and lasted for 2 or 3 weeks. He 
was a non-smoker and past medical history revealed only Gilbert syndrome. Ear, nose, teeth 
and throat examinations were negative, and he did not have any pathological neurological 
signs. Routine laboratory tests showed only a mildly increased bilirubin level, while brain 3T 
MRI was normal. The patient was not on a daily medication, and previously he had used 
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different NSAIDs (diclofenac, ibuprofen, indomethacin, nimesulide), carbamazepine and 
amitriptyline for his headache without any effect. He had taken methylprednisolone at a 1 
mg/kg daily dose on the second day of his last headache period and his pain attacks had 
completely disappeared within 48 h. To decrease the possible side-effects of the corticosteroid 
treatment, the histamine H2 receptor antagonist famotidine at a daily dose of 80 mg and 
potassium chloride at a daily dose of 1000 mg were co-administered with the 
methylprednisolone therapy. After 2 weeks’ corticosteroid therapy the daily dose was reduced 
by 8 mg every day until it was discontinued. 
 
5.3. Discussion 
In this study we treated three patients with oral administration of methylprednisolone 
in daily doses of 1 mg/kg. All patients fulfilled the International Headache Society 
classification criteria of episodic SUNCT syndrome. The headache bouts were refractory to 
all previously used medications, including different NSAIDs, antiepileptic and tricyclic 
antidepressant drugs. We have treated a total of eight SUNCT episodes with oral 
methylprednisolone in these patients, and the headache periods were completely suppressed in 
all cases.  
Based on previous reports, there is no curative on consistently effective drug treatment 
for SUNCT syndrome. Therapy of acute attacks is not a useful concept as the attacks are very 
short in duration. Furthermore, abortive therapy may result in overmedication and toxicity. 
Therefore, preventive therapy is suggested to suppress attacks and to maintain remission over 
the expected duration of the headache period. The prophylactic pharmacological therapy 
works much more effectively in episodic SUNCT than in chronic patients, and success of the 
treatment depends on the pharmacological agent and its dose. Various classes of medication 
used in other headache syndromes have been tried for the treatment of SUNCT and have had 
poor effectiveness. These include NSAIDs (indomethacin, nimesulide), analgesics 
(paracetamol, opiates), 5-HT agonists (triptans, ergotamine), b-blockers (propranolol, 
timolol), a-adrenoreceptor agonist (clonidine), tricyclic antidepressants (amitriptyline, 
nortriptyline, desipramin), calcium channel blockers (nifedipine, flunarizine, diltiazem), 
antiepileptic drugs (phenytoin, valproic acid, clonazepam), lithium and baclofen. 
 In short-term prevention intravenous and subcutaneous lidocaine provided the patients 
some pain relief up to total pain abolition. Although cardiac adverse events did not occur, 
hospitalization and cardiac monitoring were necessary. Lamotrigine given 125–400 mg/day is 
the first-line recommendation for long-term prevention, and has a good effect in achieving 
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complete remission or attack frequency reduction in most SUNCT patients. The main problem 
with lamotrigine is that the dose titration is very slow because of the possible skin reactions. 
In second-line prevention topiramate can be effective at doses of up to 300 mg/day as > 50% 
of patients had a good response to it. However, topiramate may cause severe side-effects and 
its administrationis not suggested in patients with a history of renal stones, glaucoma, 
depression, or low body weight. Gabapentin can be effective also as a second-line agent in 
SUNCT in doses ranging from 800 to 3600 mg daily. Interestingly, this drug was more 
effective in patients with shortlasting unilateral neuralgiform headache attacks with cranial 
autonomic symptoms (SUNA) (60%) than in SUNCT (45%) (12). Carbamazepine has also 
been reported as having a good effect in SUNCT at doses of up to 900 mg/day, especially 
when used in combination with steroids or topiramate.  
Although there is no evidence-based recommendation for corticosteroid use in 
SUNCT syndrome, a few case reports are known where patients were treated by prednisone, 
prednisolone or methylprednisolone with moderate to excellent therapeutic response. 
Blockade of the greater occipital nerve with steroids and local anaesthetics were also tried in 
certain cases of SUNCT and were found to have moderate or good efficacy, but this treatment 
worked better in cluster headache. Conversely, corticosteroids are advised in cluster headache 
for short-term prevention; however, randomized, placebo-controlled trials are unavailable. 
The 21-day long oral prednisolone therapy is started with 1 mg/kg (maximum 60– 100 mg) 
once daily for 5 days; thereafter the dose is decreased by 10 mg every day or every 3 days. 
With this method the risks of long-term steroid use (diabetes, hypertension) can be 
minimized. The mechanism of methylprednisolone action is unclear, although it is probably 
based on the anti-inflammatory effect of the drug. Methylprednisolone works via the 
glucocorticoid receptor by suppressing the expression of proinflammatory cytokines and also 
affecting the production of inflammatory mediators. It is known that in cluster headache the 
pain is a result of trigeminal nerve activation causing the release of vasodilative 
neurotransmitters such as substance P, serotonin (5-HT), nitric oxide, endothelins, calcitonin 
generelated peptide (CGRP), vasoactive intestinal peptide (VIP) and interleukin (IL)-1, which 
is a cytokine acting in perivascular inflammation. It has been assumed that corticosteroids 
develop their influence by moderating the level of certain neurotransmitters (CGRP, VIP, 
histamine, 5-HT) and vasoactive inflammatory agents (IL-1), thereby decreasing the 
perivascular sterile inflammation.  
In conclusion, orally administered methylprednisolone therapy proved effective in 
rapid and complete headache resolution in patients with episodic SUNCT syndrome. 
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Symptoms did not relapse at the end of the expected headache cycle when the therapy was 
discontinued. Furthermore, intolerable side-effects were not manifested during the treatment 
periods. In case of longer headache periods, corticosteroid therapy would give time for 
introduction and titration of other preventive medication. 
 
6. Summary and novel findings 
 In the thesis we investigated three different topics related to the primary headaches.  
In the first part those risk factors were analyzed in migraine patients, which can lead to 
the development of migraine related brain white matters hyperintensities. The data of 186 
migraine patient were studied including medical history, comorbidity, smoking habit, routine 
laboratory test, and the characteristics of their headache. The incidence of brain WMH in case 
of migraine patients was influenced by the duration of headache and the attack frequency. 
Also increased WMH can be observed in migraine when elevated serum homocysteine, 
cholesterol, LDL and uric acid are present. 
 In the second part of thesis we studied the possible relationship between migraine and 
Mg deficiency. An oral Mg load test was administer to detect the total body Mg deficiency in 
case of migraine patients. We found total body Mg deficiency in migraineurs. It can be 
propounded that the supplementation of Mg may prevent the development of migraine. 
In the third part, three SUNCT patients were investigated. The time-tested lamotrigine 
therapy acts only as long-term prevention therapy, because we have taper the dose very 
slowly by the possible serious skin side reaction. Analogously to the cluster headache we tried 
to treat the SUNCT periods with steroid medication. In all cases the steroid administration 
were successful, after three days of treatment the headache terminated, therefore we can 
advise the steroid to short-term prevention therapy in SUNCT headache. 
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